Unilife Announces Results of 2012 Annual General Meeting
YORK, Pa., Nov. 30, 2012 /PRNewswire/ — Unilife Corporation (“Unilife” or the “Company”) (NASDAQ: UNIS; ASX: UNS) today announced that all four of the proposed items for its 2012 Annual General Meeting of shareholders were approved by the Company’s shareholders.
The Company has posted a complete audio archive of the meeting, along with the slide show presentation and a speech from Unilife CEO Mr. Alan Shortall focusing on the Company’s commercial pipeline on its website at http://ir.unilife.com/events.cfm.
“We are fully executing our business strategy to attain a position of global leadership for injectable drug delivery systems,” Mr. Shortall said during his presentation.
“In many areas of our business, we are not just right on track….we are ahead of my original expectations. During the last two years in particular, we have built significant shareholder value by investing in R&D to introduce new proprietary technologies to our device portfolio. I am very pleased to report that this value is being embraced by a multitude of pharmaceutical companies. I would like to use this presentation to give shareholders an unprecedented glimpse into our commercial pipeline. I want to give you an understanding of the commercial, financial and strategic potential of the business that is now Unilife.”
Mr. Shortall discussed a selection of 30 active programs now progressing through Unilife’s commercial pipeline covering all of its device platforms.
About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife’s broad portfolio of proprietary device technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, long-duration subcutaneous pump delivery systems and targeted delivery systems. Each of these innovative and highly differentiated device platforms can be customized by Unilife to address specific customer, drug and patient requirements. Unilife’s global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.
Investor Contacts (US): Analyst Enquiries Investor Contacts (Australia) Media Contact Todd Fromer / Garth Russell Lynn Pieper Jeff Carter Eve McGrath KCSA Strategic Communications Westwicke Partners Unilife Corporation Rubenstein PR P: + 1 212-682-6300 P: + 1 415-202-5678 P: + 61 2 8346 6500 P: + 1 212 843-8490
SOURCE Unilife Corporation